IL6 and neoplasm: For example, targeted depletion of M2 TAMs to restore CD8+T cell cytotoxicity in advanced OC (70); inhibiting the IL-6 pathway to attenuate STAT3-mediated tumor growth promotion (71); and modulating DCs migration to increase intratumoral distribution, which may enhance anti-tumor immunity.